Optimization Of Alemtuzumab Dose For Graft-Versus-Host Disease Prophylaxis For Reduced Intensity Transplantation From Unrelated Donors For Patients With Hematologic Malignancies
Bibliographic record
Abstract
Tabled 1Table 1: Hematopoietic recovery, engraftment, acute and chronic GVHD in patients undergoing unrelated transplantation using alemtuzumab based GVHD prophylaxisCharacteristicsWhole study patients (n=36)Cohort 1 - alemtuzumab 60mg(n=17)Cohort 2 - alemtuzumab 30 mg (n=19)P value(cohort 1 vs. cohort 2)Median days to neutrophil recovery (range)19 (12-29)20 (15-29)16 (12-22)0.001Median days to platelet recovery(range)13 (9-33)14 (10-33)11 (9-24)0.10Median % donor cells on day 30 (range)98 (52-100)98 (52-100)99 (76-100)0.89Median % donor cells on day 60 (range)98 (8-100)99 (8-100)98 (87-100)0.14Median % donor cells on day 120 (range)98 (5-100)96 (5-100)98 (73-100)0.39Graft failure (Primary/ Late)2/21/11/11.00Median days to onset of acute GVHD (range)40 (9-168)46 (9-89)38 (15-168)1.00Cumulative incidence of ≥ grade 2 acute GVHD (95% CI) @ 200 days58% (44-77)59% (39-90)58 (39-87)0.98Median days to onset of chronic GVHD (range)153 (101-541)144 (101-369)174 (102-541)0.67Cumulative incidence of chronic GVHD (95% CI) @ 1-year42% (28-64)38% (19-72)47% (28-80)0.56 Open table in a new tab Of note, no cases of grade 4 acute GVHD, steroid refractory acute GVHD or severe chronic GVHD (using NIH consensus criteria on global severity of chronic GVHD) in any of the cohorts. Our data suggest that a low dose of alemtuzumab (30 mg) with CsA is an effective GVHD prophylaxis for the prevention of severe acute and chronic GVHD with acceptable risk of relapse in the setting of RIC for MUD transplantation and warrants further studies. Of note, no cases of grade 4 acute GVHD, steroid refractory acute GVHD or severe chronic GVHD (using NIH consensus criteria on global severity of chronic GVHD) in any of the cohorts. Our data suggest that a low dose of alemtuzumab (30 mg) with CsA is an effective GVHD prophylaxis for the prevention of severe acute and chronic GVHD with acceptable risk of relapse in the setting of RIC for MUD transplantation and warrants further studies.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".